Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Advanced Pancreatic Cancer
Interventions
DRUG

Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4

Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 days 1 \& 15 in a 28 days cycle

DRUG

Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4

Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle

DRUG

Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4

Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1 \& 15 in a 28 days cycle

DRUG

Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4

Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle

Trial Locations (15)

15006

Complexo Hospitalario Universitario A Coruña, A Coruña

15706

Complexo Hospitalario Universitario de Santiago, Santiago de Compostela

18014

Complejo Hospitalario Regional Virgen de Las Nieves, Granada

20014

Hospital Universitario Donostia, Donostia / San Sebastian

28007

Complejo Hospitalario Gregorio Marañón, Madrid

28034

Hospital Ramón Y Cajal, Madrid

28040

Hospital Clínico San Carlos, Madrid

Hospital Universitario Fundación Jiménez Díaz, Madrid

28050

Hospital Universitario Madrid Sanchinarro, Madrid

29010

Complejo Hospitalario Regional de Málaga, Málaga

31008

Complejo Hospitalario de Navarra, Pamplona

39008

Hospital Universitario Marqués de Valdecilla, Santander

46026

Hospital Universitari I Politècnic La Fe, Valencia

50009

Hospital Universitario Miguel Servet, Zaragoza

08035

Hospital Universitari Vall D'Hebron, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

PH Research, S.L.

OTHER